Submit Manuscript  

Article Details

The Use of Oncolytic Vaccinia Viruses in the Treatment of Cancer: A New Role for an Old Ally?

[ Vol. 5 , Issue. 4 ]


Stephen H. Thorne, David L. Bartlett and David H. Kirn   Pages 429 - 443 ( 15 )


The use of genetically engineered, tumor-targeting viruses as oncolytic agents has recently emerged as a promising new area for the development of novel cancer therapies. The first viruses to enter the clinic, such as ONYX-015 (an oncolytic adenovirus), provided evidence both for the safety and for the anti-tumor potential of this approach. The results of these early trials have also allowed investigators to examine the limitations of these viruses and to develop potentially far more effective approaches. In this review the development of such next generation viruses, in particular the potential use of strains of vaccinia virus, will be discussed. Vaccinia has an enormous history of use in humans and possesses many of the features felt to be beneficial for the creation of a successful virotherapy agent. It causes no known disease in humans, yet is capable of infecting almost all cell types with a subsequent rapid and lytic infection, which subsequently induces a vigorous local CTL immune response at the site of infection. Vaccinia also displays natural tumor tropism, and several approaches have been used to further limit viral replication to tumor cells and to optimize the immune response induced at the site of the tumor. Finally, the large cloning capacity of vaccinia allows for the addition of multiple foreign genes into the viral genome. This has been exploited to increase the bystander effect of the virus by immune modulation or by expression of pro-drug converting enzymes as well as to incorporate safety controls and reporters for in vivo molecular imaging. Initial clinical trials with these viruses further highlights their potential as the next generation of oncolytic agents and as highly effective future cancer therapies.


onyx, vaccinia strains, cell-associated enveloped virus (cev), virotherapy, immune response


JENNEREX Biotherapeutics, Mill Valley, CA, USA and Oxford University Medical School, Departmentof Pharmacology, Oxford, UK.

Read Full-Text article